Physician profile
John E Thurston
NPI 1144296245
$4,105.81
in general payments reported to CMS, 2019-2025
29 companies · $486 in 2025
The $486 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $420 · 2020: $563 · 2021: $667 · 2022: $742 · 2023: $623 · 2024: $605 · 2025: $486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $812.47 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $674.65 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $624.14 | 2019-2025 | Verquvo, Belsomra, Januvia |
| Novo Nordisk INC | $404.87 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $349.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $271.57 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $119.93 | 2019-2021 | |
| Grifols USA, LLC | $111.19 | 2019-2023 | Xembify |
| Abbvie INC. | $106.67 | 2022-2023 | Ubrelvy, Vraylar |
| Pfizer INC. | $76.41 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.37 | 2023 | |
| Harmony Biosciences LLC | $55.46 | 2024 | |
| Allergan, INC. | $48.62 | 2019-2020 | |
| Glaxosmithkline, LLC. | $43.70 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $41.67 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $33.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.68 | 2021 | |
| Radius Health, INC. | $28.94 | 2020-2023 | Tymlos |
| Eisai INC. | $28.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.79 | 2022 | |
| Corcept Therapeutics | $21.79 | 2024 | Korlym |
| Sunovion Pharmaceuticals INC. | $20.52 | 2019 | |
| Stryker Corporation | $20.48 | 2025 | Gamma |
| Ultragenyx Pharmaceutical INC. | $20.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Convatec INC. | $14.95 | 2024 | |
| Edwards Lifesciences Corporation | $14.62 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Nabriva Therapeutics, Plc | $13.07 | 2022 | |
| Bioventus LLC | $12.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Thurston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.